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ABSTRACT
Ischemic events, common in many diseases, result from decreased blood flow and impaired delivery of
oxygen and glucose to tissues of the body. While much is known about the cellular transcriptional
response to ischemia, much less is known about the posttranscriptional response to oxygen and glucose
deprivation. The goal of this project was to investigate one such posttranscriptional response, the
regulation of mRNA stability. To that end, we have identified several novel ischemia-related mRNAs that
are synergistically stabilized by oxygen and glucose deprivation including VEGF, MYC, MDM2, and CYR61.
This increase in mRNA half-life requires the synergistic effects of both low oxygen (1%) as well as low
glucose ( 1 g/L) conditions. Oxygen or glucose deprivation alone fails to initiate the response, as
exposure to either high glucose (4 g/L) or normoxic conditions inhibits the response. Furthermore, in
response to hypoxia/hypoglycemia, the identified mRNAs are released from the RNA binding protein





Ischemia is a frequent complicating factor in many cardiovascu-
lar diseases (CVD) such as heart attack and stroke. While ische-
mia results in the deprivation of many nutrients, lack of oxygen
and glucose arguably have the greatest impact on the metabo-
lism of the cell. Indeed, glucose deprivation can result in a myr-
iad of cellular effects including cell cycle arrest, apoptosis, and
autophagy.1 In response to glucose deprivation, pathways such
as mTOR/AKT and AMPK along with transcription factors
such as MYC are activated to mitigate the detrimental effects.2-4
The cellular response to hypoxia has also been well studied and
much is known about the transcriptional response that is initi-
ated upon exposure to low oxygen conditions. The main media-
tors of this response are the Hypoxia Inducible Factor (HIF)
family of transcription factors, with the oxygen-dependent HIF-
specific prolyl hydroxylases (PHDs) and the mitochondria play-
ing a critical role in the regulation of the HIF-a subunits.5-11
Interestingly, glucose levels have been shown to impact the
hypoxic stabilization and activation of the HIF pathway in mul-
tiple mammalian cell types.12-15 Indeed, while depletion of glu-
cose can prevent hypoxic HIF-1a accumulation in some cell
types,13 increased levels of glucose can also lead to attenuation
of the hypoxic HIF transcriptional response through effects on
both HIF-a stabilization and activation.12,14,15 Furthermore,
these cellular effects can have widespread implications for the
organism. For example, hyperglycemia is a common result of
poorly controlled diabetes and can result in decreased HIF-a
stabilization, contributing to many diabetic complications such
as decreased vascular density and impaired wound healing.16-19
In addition, increased blood glucose has also been shown to
impair the ability to recover from an acute hypoxic challenge
such as a myocardial infarction,20,21 and is a recognized risk
factor for CVD.22,23 Thus it is important to understand the
interplay between glucose levels and the hypoxic response as it
relates to all aspects of gene expression.24
Although the transcriptional response to hypoxia is well
established, the posttranscriptional response to oxygen and glu-
cose deprivation is less understood.25 Increases in the stability
of individual mRNAs, such as VEGF and GLUT1, have been
associated with hypoxic exposure.26 Indeed, the hypoxic post-
transcriptional regulation of VEGF has been studied in multiple
cell types.27-32 VEGF posttranscriptional regulation is reported
to involve AU Rich Elements (AREs), and multiple RNA bind-
ing proteins (RBPs) have been implicated in its regulation
including HuR, PTB, hnRNPL, and others.27,31,33-36 Specific
sequences have also been identified in the VEGF mRNA 30
UTR and ORF that contribute to this hypoxic regulation,27,31-34
but this analysis has not been extended to other mRNAs. Inter-
estingly, glucose deprivation alone, or in conjunction with
severe hypoxia/anoxia ( 0.1% O2), has been shown to lead to
stabilization of the VEGF mRNA,37-39 but the effects of hypo-
glycemia with moderate hypoxia have not been investigated.
As hypoxia/hypoglycemia can have many different effects
on gene expression, it is important to understand all aspects of
the cellular response to develop the most effective therapeutics.
Therefore, we set out to investigate the understudied
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posttranscriptional response to oxygen and glucose deprivation.
Our overall finding is that oxygen and glucose deprivation syn-
ergistically increase the mRNA stability of genes that are
important for the ischemic response.
Results
The discovery that glucose levels modulated the hypoxic
response came from attempts to replicate previous studies
which reported that VEGF mRNA half-life significantly
increased in response to exposure to 1% oxygen.29,31,33,40 How-
ever, intermittent success during preliminary investigations
revealed that VEGF mRNA was only stabilized when cells were
plated at higher densities. Reasoning that another nutrient
must be impacting the hypoxic response, several culture media
components were analyzed for their impact on VEGF mRNA
stabilization. While changes in pyruvate, glutamine, and serum
levels had no effect on the stabilization of VEGF mRNA (data
not shown), depriving rat C6 glioma cells of glucose and oxy-
gen simultaneously resulted in robust stabilization of VEGF as
well as MYC and MDM2 (Fig. 1A). It should be noted that
throughout this paper, half-life measurements are limited to
the p165A isoform of VEGFA (VEGF165) which is one of the
most abundant pro-angiogenic isoforms.35
For all of the experiments, cells were treated as described in
the material and methods. Briefly, cells maintained in high glu-
cose (4.0 g/L) media were plated at 0.5 £ 106 cell per well of a 6
well plate and allowed to recover for 18–24 hours. The next
day, media was removed and replaced with media of defined
glucose concentration and cells were placed in the hypoxia
hood set for 24 hours. Actinomycin D (ActD) treatment was
then performed over a 2 hour time course. ActD time course
was limited to 2 hours because in preliminary experiments,
mRNAs with half-lives of approximately one hour or less only
displayed exponential decay in response to ActD for approxi-
mately 2 to 4 hours (Fig. S8A) before beginning to level off.
Because of this, mRNA half-lives calculated from a full 8 hour
time course were grossly over-estimated when compared with
half-lives calculated from only the first 2 hours of the time
course which better predicted the actual time taken to decay
50% of the mRNA (Fig. S8B). Furthermore, all calculated half-
lives greater than 6 hours or those calculated to have a negative
half-life (infinitely stable) were converted to 6 hours which was
the maximum half-life reliably calculated by this method (data
not shown).
Concomitant oxygen and glucose deprivation triggers
increased mRNA stability
Initial experiments revealed that hypoxic mRNA stabilization
exhibited an inverse dose dependence on glucose in a variety of
cell types. As shown in Fig. 1A, under normoxic conditions,
altering the glucose levels from 0 to 4 g/L had no effect on the
steady-state half-lives of VEGF, MYC, or MDM2 mRNA in rat
C6 glioma cells. Similarly, when C6 cells were incubated under
hypoxic conditions (1% O2) in the presence of high glucose
(4 g/L) media for 24 hours there was no significant change in
the mRNA half-life of VEGF, MYC or MDM2. However, when
the glucose concentration was decreased to either 1 g/L (low
glucose) or 0 g/L (no glucose), there was a significant increase
in VEGF, MYC, and MDM2 mRNA half-lives in the cells cul-
tured under hypoxia for 24 hours (Fig. 1A; corresponding
decay curves can be found in Fig. S1A). These increases in
mRNA stability were mirrored by changes in overall mRNA
abundance (Fig. 1C) with hypoxic induction of mRNA
inversely correlated with glucose concentration (R2 ¡0.8) for
all 3 mRNAs.
This glucose dependence of hypoxic mRNA stabilization
was not limited to rat C6 glioma cells as it was observed in sev-
eral other cell types from both human and mouse. However,
the sensitivity of the response did vary somewhat between the
cell types. For example, the human hepatocellular carcinoma
cell line, Hep3B, required greater glucose deprivation to see the
mRNA stabilization. At both 4 and 1 g/L glucose there was no
significant stabilization of VEGF, MYC, or MDM2 mRNA
under hypoxia, however when there was a complete lack of glu-
cose (0 g/L), significant hypoxic stabilization of all 3 messages
was seen (Fig. 1B; corresponding decay curves can be found in
Fig. S1B). Interestingly, similar to the C6 cells, the hypoxic
increase of VEGF mRNA abundance was also inversely corre-
lated with the glucose levels (R2 D ¡0.98), while MYC
(R2 D ¡0.75) and MDM2 (R2 D ¡0.04) mRNA levels were less
correlated and actually decreased in abundance under hypoxia
(Fig. 1D).
The human embryonic kidney cell line, HEK293T, showed a
similar glucose response to the C6 rat glioma cells. Indeed,
while exposure of HEK293T cells to 24 hours of hypoxia in the
presence of 4 g/L glucose had no significant effect on VEGF or
MYC mRNA half-life (Fig. 2A), depletion of glucose to 1 g/L or
less resulted in significant stabilization of both messages. Inter-
estingly, MDM2 had a much longer basal half-life (4–6 hrs) in
HEK293T cells, and as such, in the experimental conditions
tested, no increase in half-life in response to hypoxic exposure
was able to be measured (Fig. 2A; corresponding decay curves
in Fig. S2A). Contrary to what was seen with the C6 cells and
the half-life results, there was a positive correlation between
overall mRNA abundance and glucose levels for VEGF (R2 D
0.96) and MYC (R2 D 0.84) and the extent of the hypoxic
increase was much lower (Fig. 2C).
mRNA stability is dependent on Oxygen level
Having determined that the response was dependent on the
extent of glucose deprivation, the dependency on the severity
of the oxygen deprivation was also tested. As with 1% oxygen,
high levels of glucose (4 g/L) coupled with exposure to 3% oxy-
gen for 24 hours, did not result in any significant change in the
half-life of either VEGF, MYC or CYR61, another mRNA target
revealed by preliminary global analysis (described in Fig. 5).
However, 3% oxygen with 1 g/L glucose induced a somewhat
variable increase in MYC and VEGF mRNA half-life while not
affecting CYR61, while complete glucose deprivation (0 g/L)
resulted in a more consistent and significant increase in the
half-life of VEGF and MYC mRNA (Fig. 2B; corresponding
decay curves in Fig. S2B) while CYR61 showed a trend of
increased mRNA half-life. Furthermore, in all cases the extent
of the hypoxic stabilization was less at 3% oxygen than it was at
1% oxygen. For example, at 1 g/L glucose MYC mRNA was
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Figure 1. Oxygen and glucose deprivation synergistically stabilize mRNA. C6 (A) or Hep3B (B) cells exposed to 24 hours of Normoxia or Hypoxia (1% O2) in the presence of
4, 1, or 0 g/L glucose before being treated with Actinomycin D for 0, 1 or 2 hours. mRNA levels of VEFG165, MYC and MDM2 were determined via qPCR, normalized to
GAPDH and 0 hour time point and half-lives determined. (C, D) Relative mRNA expression (fold change) in response to hypoxic conditions (Hypox) expressed as fold
change from normoxic values (Norm). Data represents average of N 4 § SD for each condition. P  0.05 from respective Normoxic condition.
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Figure 2. Oxygen and glucose deprivation synergistically stabilize mRNA in HEK293T cells. HEK293T cells exposed to 24 hours of Normoxia and either 1% Oxygen (A) or
3% Oxygen (B) in the presence of 4, 1, or 0 g/L glucose before being treated with Actinomycin D for 0, 1 or 2 hours. mRNA levels of VEFG165, MYC, MDM2, and CYR61
were determined via qPCR, normalized to GAPDH and 0 hour time point and half-lives determined. (C, D) Relative mRNA expression (fold change) in response to hypoxic
conditions (Hypox) expressed as fold change from normoxic values (Norm). Data represents average of N D 4 § SD for each condition. P  0.05 from respective Nor-
moxic condition.
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stabilized only 2.4-fold under 3% oxygen while incubation at
1% oxygen resulted in a 7.6-fold increase in mRNA half-life.
Similar results were seen with VEGF and CYR61 suggesting
that the extent of ischemic mRNA stabilization is dependent on
the severity of both the oxygen and glucose deprivation. Again,
mRNA abundance of VEGF, MYC, and CYR61 did not corre-
late with glucose levels or mRNA half-life, although CYR61 did
show greater hypoxic induction in 0 and 1 g/L glucose when
compared with 4 g/L (Fig. 2D).
mRNA stability affected by glucose level but not by
osmolarity
Because there was such a dramatic difference in the mRNA sta-
bility response between 1 and 4 g/L in the previous experi-
ments, glucose doses ranging from 1 to 4 g/L glucose were also
tested. As shown in Fig. 3A, VEGF, MYC, and CYR61 mRNAs
all showed a dose dependent increase in hypoxic mRNA half-
life starting around 2 g/L, with significant increases over nor-
moxic half-life evident at 1 g/L glucose for all 3 mRNAs (corre-
sponding decay curves can be found in Fig. S3A). Although
there was a significant increase in VEGF mRNA level with hyp-
oxic exposure, that increase did not correlate with mRNA half-
life or glucose level (Fig. 3C). CYR61 however, showed a signifi-
cant increase in mRNA levels under hypoxic conditions only in
the 1 g/L glucose condition and there was a strong correlation
between mRNA abundance and half-life (R2 D 0.98) and a neg-
ative correlation with glucose dose (R2 D ¡0.81).
To verify that the observed effects were due to a metabolic
response and not simply due to a change in osmolarity between
the various glucose doses, cells were also exposed to identical
doses of mannitol. As shown in Fig. 3B, HEK293T cultures in
glucose free media (0 g/L) exhibit robust mRNA stabilization
of all 3 targets tested in response to hypoxia. Addition of 4.5 g/
L glucose to the media during the hypoxic exposure completely
blocked the hypoxic mRNA stabilization response. However,
addition of 4.5 g/L mannitol had minimal effect on the stabili-
zation with all 3 targets showing an increase in hypoxic mRNA
half-life similar to glucose free media suggesting the inhibition
of the mRNA stabilization response is not due to the increase
in osmolarity (corresponding decay curves can be found in
Fig. S3B). Interestingly, CYR61 was once again the only mRNA
to show mRNA abundance changes that positively correlated
(R2 D 0.86) with the mRNA stability results (Fig. 3D).
Involvement of RNA binding proteins
Previous studies have identified HuR as well as hnRNPL as
regulators of VEGF’s mRNA stability under hypoxic condi-
tions.27,31,33,36,41,42 To test the involvement of these RNA
binding proteins in the ischemic mRNA stabilization,
siRNA-mediated knockdown was used. Preliminary experi-
ments suggested that that greatest mRNA and protein
knockdown occurred after 72 hours of siRNA treatment
(data not shown). Therefore, HEK293T cells were trans-
fected with siRNAs targeting either HuR or hnRNPL or
with a negative control siRNA for 48 hours before exposing
the cells to 24 hours of hypoxia/hypoglycemia (1% O2/1 g/L
glucose) followed by ActD decay analysis. Despite robust
knockdown of both HuR and hnRNPL protein levels
(Fig. 4C), VEGF and MYC mRNA continued to be signifi-
cantly stabilized under ischemic conditions (Fig. 4A, B; cor-
responding decay curves and mRNA expression in
Fig. S4). Similar results were seen with siRNA-mediated
knockdown of hNRNPA1/B2, and PTBP and with CRISPR-
mediated knockout of HuR (data not shown). Furthermore,
ribonucleoprotein immunoprecipitations followed by real
time PCR detection of the targets (RIP-RT) failed to detect
any changes in the ability of either HuR or hnRNPL to
bind VEGF, MYC, or other known target mRNAs (data not
shown), suggesting that these RNA binding proteins are not
directly involved in the changes to mRNA stability seen in
response to ischemia.
Multiple mRNAs are stabilized in response to hypoxia/
hypoglycemia
To identify additional mRNAs that are stabilized in response to
hypoxia, a deep sequencing experiment with HEK293T cells
treated with ActD for 0, 1, or 2 hours was conducted. RNA
from 4 biologic replicates was combined into one cDNA library
and one technical replicate was run. Raw and processed deep
sequencing data for all genes can be found in Supplemental File
2. Despite its limited statistical power, this experiment did pro-
vide valuable insight into this phenomena. For example, out of
the 17,275 genes identified as expressed in all 6 conditions
(Normoxic, Hypoxic, 0, 1, 2 hrs ActD), 1,589 mRNAs (9.2%)
showed a 2-fold or greater increase in mRNA half-life in
response to 24 hours of hypoxia/hypoglycemia (1% O2/1 g/L
glucose; Fig. 5A). In addition to CYR61 (see Fig. 3), qPCR was
used to verify several other novel mRNAs identified by this
analysis that were also stabilized in response to oxygen and glu-
cose deprivation. As shown in Fig. 5B, 4 out of 6 mRNAs tested
showed significant stabilization in response to hypoxia/hypo-
glycemia similar to MYC, while 2 that had fairly long half-lives
under the normoxic condition did not show any significant
increase under hypoxia/hypoglycemia (corresponding decay
curves and mRNA expression can be found in Fig. S5B). Fur-
thermore, while the majority of the mRNAs did not show a
detectable change in stability, a subset of mRNAs (716, 4.1%)
were also identified as less stable in response to oxygen and glu-
cose deprivation (Fig. 5A).
The list of mRNAs found to be stabilized by hypoxia/hypo-
glycemia was also used to identify potential regulators of this
response. First, all mRNAs that increased their mRNA half-life
2-fold or greater in response to oxygen and glucose deprivation
were identified and compiled into a list. Then lists of published
RNA binding protein targets identified through global methods
were compiled and the overlap between the RBP targets and
the list of stabilized mRNAs was analyzed. As shown in Fig. 5C,
this approach identified the RNA binding protein KHSRP as
one potential regulator of ischemic mRNA stabilization.
Indeed, of the 1,734 KHSRP targets identified in Winzen
et al,43 245, or 14%, overlapped with the 1,589 ischemia-stabi-
lized mRNAs, an overlap that was highly significant via normal
approximation of exact hypergeometric probability (Represen-
tation factor: 1.5, p < 1.064e¡12).
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Figure 3. mRNA stabilization is dependent on glucose concentration but not osmolarity. (A) HEK293T cells exposed to 24 hours of Normoxia or Hypoxia (1% O2) in the
presence of 4, 3, 2, or 1 g/L glucose before being treated with Actinomycin D for 0, 1 or 2 hours. (B) HEK293T cells exposed to 24 hours of Normoxia or Hypoxia (1% O2)
in the presence of glucose free DMEM alone (0) or supplemented with 4.5 g/L glucose or mannitol before being treated with Actinomycin D for 0, 1 or 2 hours. (A, B)
mRNA levels of VEFG165, MYC, and CYR61 were determined via qPCR, normalized to GAPDH and 0 hour time point and half-lives determined. (C, D) Relative mRNA
expression (fold change) in response to hypoxic conditions (Hypox) expressed as fold change from normoxic values (Norm). Data represents average of N D 5 (A, C) or 4
(B, D) § SD for each condition. P  0.05 from respective Normoxic condition.
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Role of KHSRP in the ischemic mRNA stabilization
To investigate whether KHSRP’s binding to target mRNAs was
altered in response to hypoxia/hypoglycemia, RIP-RT was per-
formed using beads labeled with normal rabbit serum as a neg-
ative control. Interestingly, unlike HuR and hnRNPL, KHSRP
binding to these mRNA targets was affected by hypoxic/hypo-
glycemic exposure. As shown in Fig. 6A, when compared with
a normal rabbit serum control IP, KHSRP-specific antibody
pull-downs from normoxic HEK293T cells cultured in the pres-
ence of low glucose (1 g/L) were enriched for known mRNA
targets such as b-catenin (BCAT), as well as our mRNAs of
interest, VEGF, MYC and CYR61 while non-targets such as
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH)
showed no such enrichment. However, when the cells were
exposed to 24 hours of hypoxia/hypoglycemia (1% O2 and 1 g/
L glucose) there was a dramatic decrease in KHSRP binding to
mRNA targets that showed stabilization under the same condi-
tions while BCAT mRNA remained associated with KHSRP.
This was not due to differing amounts of protein being pulled
down as western blots for KHSRP indicated similar amounts of
KHSRP protein in both the inputs as well as the KHSRP IP’s
(Fig. 6B) suggesting that the difference may be due to an alter-
ation in the ability of KHSRP to recognize these specific
mRNAs.
To test whether KHSRP was necessary for the ischemic sta-
bilization of these mRNAs, siRNA-mediated knockdown was
performed. Despite a robust reduction in KHSRP protein and
mRNA levels (Fig. 6C and Fig. S6C) there was no significant
inhibition of the ischemic stabilization of VEGF, MYC, or
CYR61 mRNAs (Fig. 6D; corresponding decay curves and
mRNA abundance can be found in Fig. S6). In addition, knock-
out of KHSRP by CRISPR had no significant effect on the hyp-
oxic stabilization of these messages when compared with cells
treated with a negative control CRISPR construct (Fig. S7) sug-
gesting that other RNA binding proteins or posttranscriptional
regulators are likely to be involved.
Summary
Overall, these studies have revealed that in response to oxygen
and glucose deprivation, short-lived mRNAs such as VEGF,
Figure 4. Silencing of either HuR or hnRNP L has no effect on ischemic stabilization of mRNA. HEK293T cells were transfected with siRNA targeting the RNA binding pro-
teins HuR (A), hnRNP L (B), or a negative control siRNA (Neg) for 48 hours before being exposed to 24 hours of Normoxia or Hypoxia (1% O2) in the presence of 1 g/L glu-
cose. Cells were treated with Actinomycin D for 0, 1 or 2 hours, mRNA levels of VEFG165 and MYC were determined via qPCR, normalized to GAPDH and 0 hour time point
and half-lives determined. Data represents average of N D 4 (HuR) or N D 3 (hnRNP L) § SD for each condition. P  0.05 from respective Normoxic condition. (C) Repre-
sentative western blots showing extent of knockdown (% protein remaining) for either HuR or hnRNP L normalized to tubulin loading control.
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MYC, CYR61, and others are stabilized, while high levels of
glucose appear to inhibit the response. This response is dose
dependent on both oxygen and glucose but not osmolarity.
Finally, while the RNA binding proteins HuR and hnRNPL do
not appear to be involved in the response, KHSRP does exhibit
differential binding to VEGF, MYC, and CYR61 mRNAs in
response to hypoxia/hypoglycemia although knockdown/
knockout of KHSRP is not sufficient to inhibit the response.
Discussion
The response to hypoxia involves many different changes in
gene expression.25 The transcriptional changes that occur
through the actions of the Hypoxia Inducible Factor family
have been well studied, however, there are also many posttran-
scriptional events that likely play a key role in adapting to the
nutrient deprivation as well.41,42 It has been well established
that in response to severe oxygen deprivation there is an inhibi-
tion of global cap-dependent translation with a subset of
important mRNAs continuing to be translated through several
proposed mechanisms.25,44-48 Recently, global changes in alter-
native splicing have also been shown to be involved in the hyp-
oxic response, although the therapeutic potential of these
findings is yet to be explored.49,50 Finally, it has been shown
that hypoxia alone leads to an increase in mRNA half-life of
messages such as VEGF and GLUT1, although we have had dif-
ficulty replicating those findings.26,27,31,51 We have now
expanded upon these studies to show that oxygen and glucose
deprivation synergize during cellular ischemia to initiate a
response that results in the stabilization of several mRNAs that
are known to be important for the adaptation to the ischemic
conditions including VEGF, MYC, and CYR61.
Our results clearly show that the amount of glucose present
can impact the hypoxic response at the posttranscriptional
level. We have been able to demonstrate that simultaneous dep-
rivation of oxygen and glucose results in the stabilization of
multiple mRNAs while high glucose or oxygen levels prevent
the response. While this is the first time that oxygen and glu-
cose have been shown to synergistically regulate gene expres-
sion at the posttranscriptional level, glucose has been shown to
affect the HIF transcriptional response to hypoxia. Indeed,
multiple studies have shown that decreased glucose levels result
in increased transcription of known HIF transcriptional targets
including VEGF.20,24,38,52,53 It is worth noting however, that
many of those studies relied on steady-state mRNA levels to
arrive at their conclusions and it is possible that an increase in
mRNA stability was also contributing to the increased mRNA
content. While we did also see some correlations between
mRNA steady-state levels and glucose concentration or half-
life, the effect varied between cell types and among mRNAs
suggesting that there are multiple layers of regulation occur-
ring. This may be feedback mechanisms designed to limit over-
all mRNA abundance or perhaps crosstalk between the
transcriptional and posttranscriptional pathways. These rela-
tionships will need to be explored in future studies to help
resolve this apparent disconnect.
Despite our best efforts we were unable to determine a role
for either HuR or hNRNPL in this hypoxic/hypoglycemic
response. This is curious as multiple studies have shown a role
for these RBPs in regulating VEGF mRNA stability in response
to a variety of conditions, including hypoxia.27,31,33-36,42 It is
possible that differences in cell types underlie this phenomena,
although it may also be the experimental conditions. In our
experiments, we used a hypoxic workstation which allows us to
conduct the entire experiment, including ActD treatment and
harvesting in Trizol, in a hypoxic environment, preventing any
reoxygenation from occurring. Although it is unclear for all of
the studies, at least some were conducted using hypoxic incuba-
tors which would necessitate opening (and hence reoxygena-
tion) during ActD treatment and harvest. Thus it is possible
that while HuR appears to not affect the hypoxic stabilization,
perhaps it is involved in a hypoxic cycling or reoxygenation
response.
This inability to identify the posttranscriptional player(s)
responsible for the effect prompted us to run a limited global
analysis with the idea that if related subsets of mRNAs are
being regulated similarly maybe their identity could help direct
our efforts. Our results suggest that related subsets of mRNAs
Figure 5. Global changes in mRNA stabilization in response to hypoxia/hypoglyce-
mia. (A) Ranked gene list of half-lives of all mRNAs expressed in all conditions from
deep sequencing of HEK293T cells exposed to 24 hours of normoxia or hypoxia
(1% O2) in the presence of 1 g/L glucose for 24 hours before being treated with
Actinomycin D for 0, 1 or 2 hours. Note log 2 scale of y axis. Data represent an N D
1. (B) Real time verification of mRNA half-lives determined from deep sequencing
experiment. Data represents average of N D 4 § SD for each condition. P  0.05
from respective Normoxic condition. (C) Overlap of all mRNAs identified as stabi-
lized greater than 2-fold in our study and KHSRP targets identified in Winzen et al.
#Representation factor: 1.5, p < 1.064e¡12 via normal approximation of exact
hypergeometric probability.
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Figure 6. KHSRP binding to specific mRNAs is inhibited by oxygen and glucose deprivation. HEK293T cells were exposed to 24 hours of normoxia or hypoxia (1% O2) in
the presence of 1 g/L glucose for 24 hours and then subjected to KHSRP immunoprecipitation. (A) Fold enrichments calculated from immunoprecipitated mRNA levels
normalizing to GAPDH as a negative control and the normal rabbit serum negative control IP. (B) Representative Western blot showing equivalent amounts of KHSRP pro-
tein being immunoprecipitated (IP) under Normoxic (N) or Hypoxic (H) conditions, antibody heavy chain (Ab HC) was also detected. (C) Representative western blot show-
ing extent of KHSRP protein knockdown in normoxic conditions after 72 hours siRNA treatment as compared with negative control siRNA (Neg). GAPDH protein levels
were used as a loading control. (D) HEK293T cells were transfected with siRNA targeting KHSRP or negative control siRNA (Neg) for 48 hours before being exposed to
24 hours of Normoxia or Hypoxia (1% O2) in the presence of 1 g/L glucose. Cells were treated with Actinomycin D for 0, 1 or 2 hours, mRNA levels of VEFG165 and MYC
were determined via qPCR, normalized to GAPDH and 0 hour time point and half-lives determined. Data represents average of N D 3 § SD for each condition. P  0.05
from respective Normoxic condition.
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may be regulated in concert, with many pathways related to
angiogenesis, cardiovascular disease, and cancer being over-
represented in the stabilized mRNAs. This supports the idea
that there may be hypoxic posttranscriptional RNA operons
(PTROs) that could be identified and exploited for novel thera-
peutic treatments of these diseases.54-57 Thus, these results may
have broad reaching implications for the role of mRNA stabili-
zation in both physiologic as well as pathological conditions.
We were also able to identify KHSRP as a potential RNA
binding protein involved in this response. KHSRP has been
shown to bind AU-Rich Elements (ARE) in mRNAs and target
them for degradation by the exosome.58-61 This role would
explain the mRNA stabilization response seen in our system.
Under normoxic conditions, KHSRP would bind and direct the
degradation of the mRNAs. Upon ischemic exposure, KHSRP
is no longer able to bind these mRNA and they become stabi-
lized. What controls this switch in binding upon hypoxic expo-
sure is still unknown but likely involves cellular signaling
pathways.
Many pathways such as mTOR/AKT and AMPK along with
transcription factors such as MYC are activated upon glucose
deprivation to mitigate the detrimental effects of the nutrient def-
icit.2-4 AMPK in particular has been shown to be necessary and
sufficient for an increase in VEGF and GLUT1 mRNA stability
in response to glucose deprivation.37 In the brain, glucose depri-
vation has been shown to synergize with hypoxia to increase the
stabilization of GLUT151,62 Furthermore, the p38 and JNK path-
ways has been implicated in the hypoxic stabilization of VEGF
message via HuR in rat glioma cells, as well as other transcrip-
tional, and posttranscriptional hypoxic responses.63-68
Interestingly, it has been shown that phosphorylation of
KHSRP can differentially regulate its ability to bind to spe-
cific subsets of mRNAs.43,69,70 For example, during C2C12
myogenic differentiation, phosphorylation of Threonine 692
by the P38 MAP kinase alters KHSRP’s RNA binding speci-
ficity such that it no longer binds to a subset of mRNAs
important for myogenic differentiation, thus leading to their
stabilization.69 Suprisingly, not all KHSRP targets are
released suggesting that the P38 phosphorylation impacts
only a specific subset of mRNAs. This is mirrored in our
data with VEGF and MYC being released while B-catenin
remains bound by KHSRP under hypoxia/hypoglycemia.
Studies are currently underway to determine if P38 or other
kinases may be involved in the ischemic stabilization of the
identified mRNAs.
While our RNP-IP data clearly show that hypoxia/hypogly-
cemia can alter KHSRP’s ability to bind VEGF, MYC, and
CYR61 mRNA, knockout of KHSRP appeared to have no effect
on their hypoxic mRNA stabilization. This could be due to a
couple of reasons. First, the extent of KHSRP knockdown may
have been insufficient to alter the response. While we calculated
an approximately 80% knockdown of KHSRP protein levels by
siRNA and almost 100% with CRISPR, we saw no change in
the steady mRNA half-life, mRNA level, or protein content of
VEGF, MYC, b-catenin, or other known KHSRP targets sug-
gesting that either we need even greater levels of knockdown or
that other regulators may be compensating for the loss of
KHSRP in the HEK293 cells. It is also possible that multiple
RBPs, and/or micro RNAs may be playing a role in this
response and that only by altering all of them at once may we
be able to affect the stabilization response.
Unfortunately, the functional aspects of this response have
eluded us. Despite great effort we have been unable to observe
any changes in protein level that can be attributed to the ischemic
mRNA stabilization (data not shown), suggesting that it may play
another role. It is well known that when exposed to hypoxic con-
ditions severe enough to deplete cellular ATP levels, generalized
cap-dependent translation is inhibited while certain mRNAs
(including VEGF) continue to be translated.25,44-46,48,71 It may be
that the mRNA stabilization response we are seeing is somehow
coupled to this decrease in translation. It is also possible that the
depletion of oxygen and glucose may induce stress granule for-
mation which might also be sequestering the VEGF and MYC
mRNAs and protecting them from degradation.45 However, if
this were true, we might expect that restoration of oxygen and
glucose levels to the cell might then lead to an increase in VEGF
and MYC translation using the stabilized mRNA. However, our
preliminary experiments suggest that this is not the case. Future
studies will investigate whether our culture conditions are indeed
affecting cellular ATP levels to an extent to induce stress granules
and if so what effect that might have on the mRNA degradation
machinery.
Overall we have shown that synergistic oxygen and glu-
cose deprivation can lead to the stabilization of several
mRNAs, including VEGF, MYC, and CYR61. Future studies
will delve into dissecting the signaling pathway further as
well as identifying the posttranscriptional regulators and
mRNA sequences responsible for this effect. It is our hope
that an increased understanding of all aspects of the gene




HEK293T (HEK293T/17; CRL-11268), HEP3B (Hep 3B2.1–7;
HB-8064), and C6(C6; CCL-107) cell lines were obtained
directly from ATCC and maintained in high glucose (4 g/L)
DMEM (Corning/Mediatech, 15–017-CV) supplemented with
10% FBS (Atlanta Biologicals, 511150), 2mM Glutamine
(Corning/Mediatech, 25–050CI), and 1X Pen/Strep (Corning/
Mediatech, 30–002-CI) and passaged when approximately 85–
90% confluent. Cells were tested for mycoplasma upon receipt.
For experiments, cells were plated at 0.5 £ 106 cell per well of a
6 well plate (CytoOne, USA Scientific, CC7682–7506) in high
glucose (4.0 g/L) media and allowed to attach/recover for 18–
24 hours. The next day, the media was removed and replaced
with media of defined glucose concentration. Hypoxic treat-
ments were performed in a Ruskin InVivo 400 Hypoxia Hood
(The Baker Company) maintained at 37C, 5% CO2, 70%
humidity and 1% oxygen. All other chemical reagents were
obtained from Sigma-Aldrich unless otherwise specified.
RNA extraction
Trizol (Life Technologies, 15596018) was used for all RNA
extractions according to the manufacturer’s protocol. For RNA
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extraction from ribonucleoprotein immunoprecipitations
(RNP-IP), GlycoBlue (Life Technologies, AM9516) was added
as a carrier during the precipitation step. RNA quality and
quantity was determined via NanoDrop 1000 (ThermoFisher
Scientific).
PCR
Reverse transcription was performed on 1 mg of total RNA in a
20 ml reaction with the iScript cDNA synthesis kit (Bio-Rad
Laboratories, 170–8891). After diluting cDNA 5-fold, quantita-
tive real-time PCR was performed using a Roche Lightcycler 96
with Fast Start Essential DNA Green (Roche Diagnostics Cor-
poration, 06–924–204–001) and primers from Integrated DNA
Technologies, Inc. Primers used are listed in Table S1. Primer
efficiency was verified to be over 95% for all primer sets used.
Quantification of mRNA was performed via DDCT analysis
using GAPDH mRNA and the respective control condition for
normalization. All real-time PCR primer sets were designed so
the products would span at least one intron (> 1kb when possi-
ble), and amplification of a single product was confirmed by
agarose gel visualization and/or melting curve analysis.
mRNA Decay rates
mRNA levels were determined by real-time quantitative PCR at
0, 1, or 2, hours after the addition of 5 mg/ml Actinomycin D
(Sigma Aldrich, A9415). GAPDH mRNA and time 0, untreated
controls were used for DDCT normalization. Half-lives were
determined by first calculating the slope of the natural log (Ln)
of the concentration versus time data and then using that value
(λ) to calculate half-life via the equation HL D (Ln(2)/λ). All
half-lives >6 hours or those calculated to have a negative half-
life (infinitely stable) were converted to 6 hours which was the
maximum half-life reliably calculated by this method.
Western blots
Whole cell lysates were prepared in whole cell extract buffer
(WCEB: 50 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA,
0.1% SDS, and protease inhibitor cocktail (ThermoFisher Sci-
entific, 88660)). Equal amounts of protein (30–50 mg) were
electrophoresed on a mini-PROTEAN any KD acrylamide gel
(Bio-Rad Laboratories, 456–9034) and transferred to Hybond
ECL nitrocellulose (GE Healthcare, RPN303D). Transfer was
verified via Ponceau S staining then blot was blocked with 5%
nonfat dry milk (LabScientific, 732–291–1940) in Tris buffered
saline with 0.1% Tween 20 (TBST) for one hour at room tem-
perature, followed by primary antibody in blocking buffer over-
night at 4C. After washing extensively with TBST, blots were
incubated for 1–2 hours at room temperature with appropriate
HRP-linked secondary antibody (GE Healthcare), washed again
with TBST, developed using Pierce ECL Western Blotting Sub-
strate (ThermoFisher Scientific, 32106), and exposed to film for
detection. Primary antibodies used, their catalog numbers and
their concentrations can be found in Table S2.
siRNA transfections
siRNAs (Silencer or Silencer Select; Life Technologies) were
transfected using Lipofectamine 2000 (Life Technologies,
11668–019) as per manufacturer’s protocol using 100 pM siR-
NAs/well of a 6 well plate. For each target, 2 independent siR-
NAs were used to confirm results. Part numbers and siRNA
IDs can be found in Table S3.
Ribonucleoprotein immunoprecipitation
Ribonucleoprotein Immunoprecipitation (RNP-IP) reactions
were performed as described previously.72,73 Briefly, cells were
lysed in polysomal lysis buffer (PLB: 100 mM KCl, 5 mM
MgCl2, 10 mM HEPES (pH 7.0), 0.5% NP40, 1 mM DTT, 100
units/ml RNase Out (Life Technologies, 10777–019) and prote-
ase inhibitor cocktail), pre-cleared, and protein concentration
determined via Pierce BCA Assay (ThermoFisher Scientific,
23225). 4 mg of cell lysate were added to protein G sepharose
beads (Sigma-Aldrich, P3296) in NT2 (50 mM Tris (pH 7.4),
150 mM NaCl, 1 mM MgCl2, 0.05% Nondiet P-40) pre-bound
to either KHSRP Antibody (Bethyl Laboratories, A302–022A)
or normal rabbit serum (Sigma-Aldrich, R9133) as a negative
control, and the reaction mixtures were tumbled for 4 hours at
4C. Beads were thoroughly washed with NT2 and then
extracted in either WCEB for Western blotting or 1 ml of Trizol
for RNA isolation.
Deep sequencing and data analysis
For deep sequencing analysis, 2.5 mg of total RNA from 4 bio-
logic replicates were combined into one sample for sequencing
due to financial constraints. The RNA was further purified via
Ambion Purelink column (ThermoFisher Scientific, 12183020)
and submitted to Beckman Coulter Genomics for library gener-
ation, sequencing and gene and mRNA isoform expression
analysis. Six libraries (Normoxia and Hypoxia at 0, 1, 2 hrs
ActD) were constructed and paired-end sequenced via Illumina
technology. 186,651,585 read pairs (1.1 lane equivalent) were
produced, resulting in >30 million read pairs per sample. Data
was returned as Fragments Per Kilobase of exon per Million
fragments (FPKM) as calculated by Cuffdif based on Cufflinks
gene identification from TopHat-aligned sequences. For analy-
sis details see the Study Report from Beckman Coulter Geno-
mics in Supplemental File 1. Data were then filtered to only
retain genes that had a non-zero value in all 6 of the samples
and half-lives were determined by calculating the slope of the
natural log (Ln) of the concentration vs. time data and then
using that value (λ) to calculate half-life via the equation HL D
(Ln(2)/λ). Finally all half-life values less than zero (infinitely
stable) or greater than 6 hours (the upper limit of our experi-
mental design) were converted to 6 hours to allow for down-
stream analysis. Raw and processed deep sequencing data for
all genes can be found in Supplemental File 2.
Statistical analysis
All experiments were performed on at least 3 separate occa-
sions to generate biologic replicates. qPCR was performed at
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least twice on each cDNA for technical verification of data.
Half-lives were calculated for each biologic replicate and then
averaged together to determine final value and standard devia-
tion of experiment. Statistical significance was calculated by a
2-tailed, paired Student’s t-test comparing experimental to con-
trol conditions. A P-value below 0.05 was defined as statistically
significant. For mRNA abundance, statistical significance was
calculated by a 2-tailed, paired Student’s t-test comparing nor-
moxic and hypoxic dCT values. A P-value below 0.05 was
defined as statistically significant. Pearson correlation coeffi-
cients were used to determine the relationship of mRNA abun-
dance with mRNA stability and glucose concentrations and
absolute R2 values  0.80 were considered reportable.
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